Detalles de la búsqueda
1.
[Efficacy and safety of VRD regimen of autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma].
Zhonghua Nei Ke Za Zhi;
62(7): 819-825, 2023 Jul 01.
Artículo
en Zh
| MEDLINE | ID: mdl-37394852
2.
[Efficacy of total oral regimens containing ixazomib in patients with relapsed and refractory multiple myeloma].
Zhonghua Nei Ke Za Zhi;
61(1): 95-98, 2022 Jan 01.
Artículo
en Zh
| MEDLINE | ID: mdl-34979777
3.
[The expression level of secretory mature B cell surface antigen in primary diagnosed multiple myeloma and its clinical significance].
Zhonghua Yi Xue Za Zhi;
102(30): 2351-2356, 2022 Aug 16.
Artículo
en Zh
| MEDLINE | ID: mdl-35970793
4.
[A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis].
Zhonghua Xue Ye Xue Za Zhi;
43(4): 330-335, 2022 Apr 14.
Artículo
en Zh
| MEDLINE | ID: mdl-35680633
5.
[Efficacy and safety of lenalidomide combined with bortezomib and dexamethasone induction therapy in newly diagnosed patients with multiple myeloma].
Zhonghua Xue Ye Xue Za Zhi;
43(8): 657-662, 2022 Aug 14.
Artículo
en Zh
| MEDLINE | ID: mdl-36709150
6.
[Allogeneic CAR-T for treatment of relapsed and/or refractory multiple myeloma: four cases report and literatures review].
Zhonghua Xue Ye Xue Za Zhi;
40(8): 650-655, 2019 Aug 14.
Artículo
en Zh
| MEDLINE | ID: mdl-31495131
7.
[Clinical implication of minimal residual disease monitoring by 10-color flow cytometry in multiple myeloma].
Zhonghua Xue Ye Xue Za Zhi;
40(9): 720-725, 2019 Sep 14.
Artículo
en Zh
| MEDLINE | ID: mdl-31648471
8.
[Efficacy and safety of bendamustine combined with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma].
Zhonghua Xue Ye Xue Za Zhi;
44(6): 504-507, 2023 Jun 14.
Artículo
en Zh
| MEDLINE | ID: mdl-37550209
9.
[Comparison of next-generation flow cytometry and next-generation sequencing in the assessment of minimal residual disease in multiple myeloma].
Zhonghua Xue Ye Xue Za Zhi;
44(4): 328-332, 2023 Apr 14.
Artículo
en Zh
| MEDLINE | ID: mdl-37357003
Resultados
1 -
9
de 9
1
Próxima >
>>